Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089708 · ClinicalTrials.gov registry record · Phase 4
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT05089708 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 123 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05089708, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants
Conditions Studied
Interventions
- DRUG Trifarotene Cream
- DRUG Trifarotene Vehicle Cream
Study Locations (20)
California
- Galderma Investigational Site #8636 - Fountain Valley
- Galderma Investigational Site #8224 - Fremont
- Galderma Investigational Site #8358 - San Diego
- Galderma Investigational Site #9955 - San Diego
Florida
- Galderma Investigational Site #7012 - Lutz
- Galderma Investigational Site #8184 - Maitland
- Galderma Investigational Site #8764 - Tampa
New York
- Galderma Investigational Site #8620 - New York
- Galderma Investigational Site #9956 - New York
- Galderma Investigational Site #9949 - New York
Louisiana
- Galderma Investigational Site #9952 - Baton Rouge
- Galderma Investigational Site #8606 - New Orleans
Maryland
- Galderma Investigational Site #8012 - Glenn Dale
- Galderma Investigational Site #9948 - Hyattsville
Indiana
- Galderma Investigational Site #9950 - Evansville
Michigan
- Galderma Investigational Site #8554 - Detroit
Nevada
- Galderma Investigational Site #8108 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05089708
The ClinicalTrials.gov registry entry for NCT05089708 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Trifarotene Cream is the first listed.
NCT05089708 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05089708 about?
NCT05089708 is a clinical study titled "AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation". The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne ...
What is the current status of trial NCT05089708?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2021-12-22. Estimated completion is 2022-12-15.
What conditions does trial NCT05089708 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT05089708?
The interventions under investigation include: Trifarotene Cream (DRUG), Trifarotene Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT05089708?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05089708 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
-
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.